Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ GPR65 Polyclonal Antibody
Rabbit Polyclonal Antibody
Supplier: Invitrogen™ PA132515
Description
PA1-32515 detects GPR65 from human samples.
GPR65 also known as TDAG8 is a transmembrane protein belonging to the G protein coupled receptor super family with 337-amino acid and 90% similarity and 81% identity in the 7 transmembrane domains of its mouse homolog. It has 3 potential N-linked glycosylation sites and is expressed predominantly in lymphoid organs and cancer tissues with increased expression during activation-induced death of T-cell hybridomas. Two major transcripts of 4.5 kb and 1.8 kb are found in peripheral blood leukocytes and functions as a novel proton-sensing receptor. It couples to adenylyl cyclase and psychosine and is also actively involved in the establishment of immunological autotolerance. GPR65 has a role in cellular transformation by RhoA activation and actin rearrangement under conditions accompanying tissue acidosis.
Specifications
GPR65 | |
Polyclonal | |
Unconjugated | |
GPR65 | |
Dig1; G protein-coupled receptor 65; Gpcr25; Gpr65; G-protein coupled receptor 25; G-protein coupled receptor 65; hTDAG8; Psychosine receptor; T cell death associated protein 8; T-cell death-associated gene 8 protein; TDAG8 | |
Rabbit | |
Antigen affinity chromatography | |
RUO | |
8477 | |
Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles. | |
Liquid |
Immunohistochemistry (Paraffin) | |
1 mg/mL | |
PBS with 0.1% sodium azide | |
Q8IYL9 | |
GPR65 | |
Synthetic 16 amino acid peptide from 1st cytoplasmic domain of human GPR65. | |
25 μg | |
Primary | |
Human | |
Antibody | |
IgG |
Safety and Handling
WARNING: Cancer - www.P65Warnings.ca.gov
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction